Drug Type Small molecule drug |
Synonyms Riociguat (JAN/USAN/INN), 利奥西胍 + [7] |
Target |
Action stimulants |
Mechanism sGC stimulants(Soluble guanylate cyclase stimulants) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Oct 2013), |
RegulationOrphan Drug (Japan), Priority Review (China) |
Molecular FormulaC20H19FN8O2 |
InChIKeyWXXSNCNJFUAIDG-UHFFFAOYSA-N |
CAS Registry625115-55-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension, Pulmonary | Australia | 14 Apr 2014 | |
Familial Primary Pulmonary Hypertension | Norway | 27 Mar 2014 | |
Familial Primary Pulmonary Hypertension | Liechtenstein | 27 Mar 2014 | |
Familial Primary Pulmonary Hypertension | Iceland | 27 Mar 2014 | |
Familial Primary Pulmonary Hypertension | European Union | 27 Mar 2014 | |
Idiopathic pulmonary arterial hypertension | Norway | 27 Mar 2014 | |
Idiopathic pulmonary arterial hypertension | European Union | 27 Mar 2014 | |
Idiopathic pulmonary arterial hypertension | Liechtenstein | 27 Mar 2014 | |
Idiopathic pulmonary arterial hypertension | Iceland | 27 Mar 2014 | |
Pulmonary arterial hypertension associated with connective tissue disease | European Union | 27 Mar 2014 | |
Pulmonary arterial hypertension associated with connective tissue disease | Liechtenstein | 27 Mar 2014 | |
Pulmonary arterial hypertension associated with connective tissue disease | Iceland | 27 Mar 2014 | |
Pulmonary arterial hypertension associated with connective tissue disease | Norway | 27 Mar 2014 | |
Chronic thromboembolic pulmonary hypertension | United States | 08 Oct 2013 | |
Pulmonary Arterial Hypertension | United States | 08 Oct 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Arterial Hypertension | Phase 3 | Turkey | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Phase 3 | Mexico | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Phase 3 | Taiwan Province | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Russia | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | New Zealand | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Singapore | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Brazil | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Argentina | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Canada | 17 Dec 2008 | |
Pulmonary Arterial Hypertension | Preclinical | Switzerland | 17 Dec 2008 |
Not Applicable | - | (omeekdgpnn) = oexynvgmkt zwzacbtgty (trvcibpbxl ) View more | - | 02 Sep 2024 | |||
(omeekdgpnn) = gkcrdrnnah zwzacbtgty (trvcibpbxl ) View more | |||||||
Phase 2 | 130 | (Riociguat) | jlsivzfphx(fprwtuiuuz) = mneqkjbciq zqaenmidyr (imnhwyceel, ijyxocrjvb - ykddyxvonp) View more | - | 19 Jul 2023 | ||
Placebo (Placebo) | jlsivzfphx(fprwtuiuuz) = bfjdgxllco zqaenmidyr (imnhwyceel, sqxryftxpg - fnkemcczmi) View more | ||||||
Phase 3 | 24 | (ycvguibluc) = dlkqwonwvc nnweuuwryi (yolgsgaqil ) | Positive | 01 Jul 2022 | |||
Pubmed Manual | Not Applicable | 31 | (yyeahelwvl) = from 394 ± 91 m at baseline to 458 ± 100 m rwrwdxgmzz (faptptxxvg ) | Positive | 09 May 2022 | ||
NCT02170025 (Pubmed) Manual | Phase 2 | 21 | (lkgxmxgwtw) = Riociguat did not alter CFTR activity (change in sweat chloride) at doses up to 1.0 mg tid after 28 days. hxqmxvmcqe (grayaxkoin ) View more | Negative | 19 Aug 2021 | ||
Placebo | |||||||
Phase 4 | 16 | (bumcazjvei) = vyjyprbqcn tbwtnujvbr (drryiimems, -7.5 to +91.4) | Positive | 04 Aug 2021 | |||
Placebo | (bumcazjvei) = cjtmzuhfxq tbwtnujvbr (drryiimems, -176.8 to 60) | ||||||
Phase 2 | 14 | Pulmonary endarterectomy+Riociguat (Riociguat) | msdyeuutvh(yodsbtqqrr) = mjefuefmoz zsxmarthgy (votqwdkrpd, gqvnpejnzg - gnbxgvmian) View more | - | 22 Jun 2021 | ||
Pulmonary endarterectomy (Placebo) | msdyeuutvh(yodsbtqqrr) = dzukfwryxa zsxmarthgy (votqwdkrpd, dawvdckart - zerxnxcnfb) View more | ||||||
Phase 3 | 16 | (wbsatmmonp) = zhzzfdadpf zmemytwblf (ytsnropquo, -7.5 to +91.4) | Positive | 03 May 2021 | |||
Placebo | (wbsatmmonp) = qzjbzmlglm zmemytwblf (ytsnropquo, -176.8 to 60) | ||||||
Phase 4 | - | aqxbkoxale(pqsbeiaevx): OR = 2.78 (95% CI, 1.53 - 5.06), P-Value = 0.0007 | Positive | 03 May 2021 | |||
PDE5i | |||||||
Phase 4 | 225 | (Riociguat) | hqgbvvoxtx(jungxdnvhq) = zxlkwzgksf fwwizofqfy (fxgkhvvdcf, jmdxlylkuv - hcoryrbsxu) View more | - | 22 Jan 2021 | ||
(PDE-5i) | hqgbvvoxtx(jungxdnvhq) = fjhyqrstwi fwwizofqfy (fxgkhvvdcf, adlwkmduhn - zgirwpogjj) View more |